Keryx Biopharmaceuticals Announces Appointment of Greg Madison to Its Board of Directors
10. März 2015 16:55 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, March 10, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced the appointment of Mr. Greg Madison, the Company's President and Chief...
Keryx Biopharmaceuticals Announces Publication of Auryxia(TM) (ferric citrate) Analysis in Journal of the American Society of Nephrology
04. März 2015 07:45 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, March 4, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced the publication of Auryxia™ (ferric citrate) data and expert analyses in...
Keryx Announces Fourth Quarter and Year-End 2014 Financial Results
27. Februar 2015 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease...
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
25. Februar 2015 16:10 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that corporate presentations will be delivered at the following upcoming investor...
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2014 Financial Results
18. Februar 2015 08:00 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal...
Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
21. Januar 2015 19:53 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced the pricing of an underwritten public offering of common stock consisting of 9,166,667 shares...
Keryx Biopharmaceuticals, Inc. Announces $100 Million Proposed Public Offering of Common Stock
20. Januar 2015 16:05 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, Jan. 20, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that it has commenced a $100 million underwritten public offering of shares of its common...
Keryx Biopharmaceuticals Announces Transition of Leadership
11. Januar 2015 22:00 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK and BOSTON, Jan. 11, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced it will be transitioning the role of Chief Executive Officer from...
Keryx Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
07. Januar 2015 07:30 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 33rd Annual...
Keryx Biopharmaceuticals Announces Commercial Launch of AURYXIA(TM) (ferric citrate) Tablets in the United States
22. Dezember 2014 07:30 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced it has begun shipping AURYXIA™ (ferric citrate) tablets to wholesalers in...